Cytokinetics, Incorporated - Laporan Laba Rugi (TTM)

Cytokinetics, Incorporated
US ˙ NasdaqGS ˙ US23282W6057

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Cytokinetics, Incorporated menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 54 56 59 58 22 70 65 151 148 95 98 10 8 8 4 3 3 18 19 86
Change (%) 2.78 4.88 -1.28 -62.72 226.81 -7.67 132.44 -1.93 -36.19 3.66 -89.85 -21.47 -3.65 -50.17 -16.47 2.71 473.90 4.03 346.13
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 86 97 107 121 146 160 174 195 209 241 274 300 320 330 332 329 331 339 358 391
Change (%) 12.65 10.13 13.72 19.96 9.80 8.99 11.87 7.33 15.06 13.91 9.50 6.59 3.11 0.65 -1.08 0.63 2.62 5.38 9.21
% of Revenue 158.44 173.66 182.36 210.08 675.92 227.09 268.06 129.01 141.19 254.59 279.75 3,018.16 4,096.80 4,384.10 8,855.86 10,487.40 10,275.09 1,837.22 1,861.17 455.62
Gross Operating Profit -32 -41 -48 -64 -124 -90 -109 -44 -61 -146 -176 -290 -312 -323 -329 -326 -328 -321 -338 -305
Change (%) 29.54 17.27 31.94 95.06 -27.88 22.09 -59.88 39.28 139.47 20.53 64.78 7.55 3.28 1.84 -0.91 0.61 -2.02 5.46 -9.92
% of Revenue -58.44 -73.66 -82.36 -110.08 -575.92 -127.09 -168.06 -29.01 -41.19 -154.59 -179.75 -2,918.16 -3,996.80 -4,284.10 -8,755.86 -10,387.40 -10,175.09 -1,737.22 -1,761.17 -355.62
SG&A 49 53 56 63 77 97 114 136 158 178 195 192 183 174 169 181 197 215 227 242
Change (%) 6.72 5.96 12.57 22.06 25.87 18.05 18.83 16.22 12.78 9.32 -1.54 -4.23 -5.37 -2.40 6.55 9.16 9.25 5.51 6.56
% of Revenue 91.12 94.61 95.59 109.00 356.87 137.45 175.73 89.84 106.46 188.16 198.44 1,925.02 2,347.63 2,305.60 4,516.18 5,760.98 6,122.71 1,165.50 1,182.14 282.35
R&D
Change (%)
% of Revenue
OpEx 136 150 163 184 223 257 289 331 367 419 469 492 504 504 502 509 528 555 585 633
Change (%) 10.48 8.66 13.33 20.68 15.35 12.40 14.62 10.98 14.08 11.96 4.92 2.38 0.02 -0.40 1.50 3.66 5.09 5.43 8.18
% of Revenue 249.57 268.27 277.95 319.08 1,032.79 364.54 443.79 218.84 247.66 442.75 478.18 4,943.18 6,444.43 6,689.71 13,372.04 16,248.37 16,397.79 3,002.72 3,043.30 737.96
Operating Income -81 -94 -104 -127 -201 -186 -224 -180 -219 -324 -371 -482 -496 -496 -498 -506 -525 -536 -566 -547
Change (%) 15.63 10.91 21.54 58.74 -7.31 19.99 -19.65 21.84 48.12 14.38 29.98 2.87 0.08 0.36 1.63 3.66 2.22 5.48 -3.30
% of Revenue -149.57 -168.27 -177.95 -219.08 -932.79 -264.54 -343.79 -118.84 -147.66 -342.75 -378.18 -4,843.18 -6,344.43 -6,589.71 -13,272.04 -16,148.37 -16,297.79 -2,902.72 -2,943.30 -637.96
Interest Expense -37 -39 -36 -33 -31 -29 -32 -35 -43 -51 -55 -59 -57 -58 -62 -73 -81 -87 -92 -92
Change (%) 3.77 -7.71 -8.01 -7.07 -3.87 8.62 9.00 24.91 17.94 7.68 6.46 -3.02 1.40 7.07 17.70 11.42 6.83 6.50 -0.04
% of Revenue -68.62 -69.28 -60.96 -56.80 -141.59 -41.65 -48.99 -22.97 -29.26 -54.08 -56.18 -589.27 -727.74 -765.84 -1,645.74 -2,319.08 -2,515.75 -468.29 -479.43 -107.42
Net Income -114 -127 -135 -156 -229 -215 -258 -216 -282 -389 -431 -540 -527 -526 -531 -545 -576 -590 -615 -606
Change (%) 11.66 6.05 15.39 46.81 -5.84 19.66 -16.20 30.67 37.86 10.76 25.26 -2.39 -0.09 0.83 2.77 5.71 2.28 4.37 -1.45
% of Revenue -209.88 -228.00 -230.55 -269.48 -1,061.13 -305.72 -396.22 -142.85 -190.34 -411.21 -439.35 -5,422.19 -6,739.96 -6,988.63 -14,141.74 -17,398.82 -17,906.24 -3,191.11 -3,201.47 -707.17

Source: Capital IQ

Other Listings
IT:1CYTK € 44.00
DE:KK3A € 42.20
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista